Inflammatory markers in coronary heart disease

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study

(2011) Heart Protection Study Collaborative Group   LANCET

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults

(2010) et al.   CIRCULATION

Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality

(2010)   JOURNAL OF INTERNAL MEDICINE

Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome

(2010) Xiu-ren Gao et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

(2009) J. Kastrup et al.   EUROPEAN HEART JOURNAL

Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community

(2009) Olle Melander   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction

(2008) Paul M Ridker et al.   CIRCULATION

Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts

(2008) Tina Shah et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

(2008) Emile R. Mohler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population

(2008) Lori B. Daniels et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE